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1INTRODUCTION
 Chronic  Obstructive  Pulmonary  Disease  (COPD),  is  a
devastating lung disease which leads to progressive difficulty in
breathing.   COPD   prevelance   and   mortality    are    continuing   to
increase despite   adequate  measures  due to continued exposure  to risk
factors   especially   smoking    among  women and  adolescents.  GOLD
estimates suggest that COPD will rise from sixth to third  most common
cause of death by 2020.The cost on health resources is immense.
COPD   (Chronic  Obstructive  Pulmonary  Disease)  is  an
umbrella  term  used  to  describe  lung  disease  associated with  airflow
obstruction which is not reversible. Mostly, emphysema and chronic
bronchitis,  either  alone  or  combined,  come in  this  category.  There  is  a
debate  whether this term also includes asthma.  However, as a general
rule, it is not included.  Although it does have obstructive components, it
is  reversible and is considered a restrictive lung disease.  Many patients
with  COPD   also  have   an   asthmatic   component   to   their  illness  as
well.
2Usually the severity of  COPD is graded based on only Forced
Expiratory Volume (FEV1). As COPD is a multisystem disorder FEV1
alone cannot determine the outcome in these patients. Hence a
multidimensional grading system was designed which included four
variables body-mass index (B), the   degree of airflow obstruction (O)
and dyspnea (D), and exercise capacity (E) measured by the six-minute–
walk test.
3AIMS AND OBJECTIVES
1. To correlate severity of BODE index to severity of
Pulmonary    Hypertension.
2. To predict future respiratory admissions based on the disease
severity  as  assesed  by  BODE  index  and  Pulmonary
Hypertension.
3. By initiating appropiate and adequate therapy along with
cardiopulmonary rehabilitation measures whether the
severity of BODE      index can be downsized.
4REVIEW OF LITERATURE COPD
 DEFINITION
Chronic obstructive pulmonary disease (COPD) has been
defined by the Global Initiative for Chronic Obstructive Lung
Disease(GOLD)1,an international collaborative effort to improve
awareness ,diagnosis and treatment of COPD ,as a disease state
characterized by airflow limitation that is not fully reversible .
COPD includes emphysema ,an anatomically defined
condition characterized by destruction and enlargement of lung
alveoli;chronic bronchitis ,a clinical condition with chronic cough and
phlegm;  and  small  airways  disease  ,a  condition  in  which  small
bronchioles are narrowed .COPD is present only if chronic airflow
obstruction occurs; chronic bronchitis without chronic airflow
obstruction is not included within COPD.
Chronic bronchitis is clinically defined as chronic productive
cough for three consecutive months in two consecutive years.
Emphysema,  pathologically defined  ‘as an abnormal
enlargement  of  the  air  spaces  distal  to  the  terminal  bronchioles
accompanied by destruction of their walls and with absence of fibrosis’.2
5COPD, though considered a chronic, debilitating disease, can be slowed
down  if    given   appropriate   management.    Bronchodialators  ,
mucolytics,  nasal oxygen and cardiopulmonary rehabilitation go a long
way in slowing the progression
EPIDEMIOLOGY
At least 10 percent of the world’s population over 40 years of
age may have chronic obstructive pulmonary disease (COPD),
according to new data (3).  The  new statistics,   suggest  that  the  chronic
lung disease is 3 times more common than previous estimates (4, 5, 6, 7).
The World Health Organization (WHO) estimates that COPD
kills more than 2.75 million people each year.  Worldwide it ranks as the
fourth leading cause of death, alongside HIV/AIDS (7). .“COPD is like
an iceberg: The burden of disease that is the tip of the problem. COPD
is rapidly increasing in prevalence, but also many people  are unaware
of  the disease that they  have .
Effective treatments exist that can improve the lives of people
with COPD and can slow the progression of the disease, but patients can
only  receive  the  benefits  of  these  therapies  if  we  stop  ignoring  COPD
and increase our awareness.
6Most national statistics on COPD have been based on the
proportion of the population that is being treated for COPD.  The
disease however, remains undiagnosed until it is already quite advanced
so this method is likely to underestimate the proportion of the
population that has COPD.
In  2010,  almost   24   million   adults  over  the   age  of   40
in India had COPD. It is  expected  that this number to increase 34% to
approximately 32 million by 2020.  The most obvious explanation for
this is  that  COPD is predominately a disease of men and only 40% of
cases in India occur in women. The strong association between age and
COPD  means  that  the  prevalence  of  COPD  in  the  future  will  be
especially sensitive to the increased survival that will result as access to
healthcare increases; even though the disease is irreversible, its progress
can be significantly slowed by  quitting smoking and seeking medical
care. Fewer than half of the estimated 23.68 million prevalent cases in
2010 were in the population between the ages of 40 and 60 years (8.25
million), which indicates that chronic obstructive pulmonary disease
(COPD)  is  a  disease  of  the  aged  in  India.  The  number  of  men  with
COPD in 2010 (approximately 14.11 million) was one and a half times
the number of women with COPD in 2010 (approximately 9.57 million);
7the most obvious explanation for this  is the higher smoking rates in men
than women in India.
The prevalence of COPD reported in different population
based studies from India is highly variable7. According to some studies,
in male subjects prevalence rate  is about   2.12%  to  9.4%   from  North
India  and  1.4%  to  4.08%   from South India. The respective ranges for
female subjects  vary from 1.33% to 4.9% in the North and from  2.55%
to 2.7% in South India. For  rounded-off  median  prevalence  rates
were assessed as 5 percent for male and 2.7 percent for female subjects
of  over  30  years  of  age7. The disease is distinctly more common in
males.
The prevalence was found to increase with increasing age,
especially in the males,in those with more than 20 pack–yrs of smoking
and in low income subjects. The male to female ratio had varied from
1.32:1 to 2.6:1 in different  studies with a median ratio of 1.6:1(11).
RISK FACTORS
1. Tobacco smoke
 Tobacco smoke, some say contains more than  4000 chemical
constituents, is the most important cause. Both cigarette and ‘bidi’
8smoking are equally dangerous.8 Various other forms of smoking like
pipe smoking and hookah  are also important in causing COPD. There is
no reliable information on smoking associated COPD in women in
whom the overall prevalence of smoking is very low. Besides active
tobacco smoking, exposure to smoking from others i.e. passive smoking,
better termed as Environmental Tobacco Smoke (ETS) exposure, may
also play a contributory role especially in nonsmoker individuals in
women.(9,10)
INDOOR AND OUTDOOR POLLUTION
Certain  solid fuels such as dried dung, wood and crop residue
used for cooking and heating is an important cause of pollution of the
indoor  air.  It  is  responsible  for  a  large  number  of   COPD   patients
especially  women in particular.11-14
Exhausts from vehicles and industrial units; dusts, fumes and
smoke from burning of crop residues in the field constitute important
sources of air pollution. Chronic exposure to polluted air is an important
cause of chronic respiratory diseases such as the COPD.15-18
9GENETIC RISK FACTORS:
Homozygosity for the Z allele of the alpha1-antitrypsin gene is
the only established risk factor. Heterozygotes for the Z allele may also
be at  risk.  Mutations involving the structure of alpha1-antitrypsin or
the regulation of gene expression have been identified as risk factors.
Alpha1-antichymotrypsin, alpha2-macroglobulin, vitamin D-binding
protein and blood group antigens, have been associated with the
development of COPD.
OTHER  RISK  FACTORS :
1. GENDER: Some studies show that the prevelance of disease in
developed countries is almost equal18.But many studies have
proven that females are susceptible to tobacco than males(19-21)
2. RESPIRATORY INFECTIONS during childhood
3. LOW SOCIOECONOMIC STATUS
4. CO MORBIDITIES
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SYMPTOMS:
Typically, after smoking 20 or more cigarettes a day for more
than twenty years, patients with COPD come to the hospital.
1. Symptoms due to emphysema
 Patients affected predominantly by emphysema, shortness of
breath may be the major symptom. Dyspnea usually is most
noticeable during increased physical activity, but as emphysema
progresses, dyspnea occurs at rest.
2. Symptoms due to chronic bronchitis
 Chronic cough with sputum is the main symptom. The sputum is
usually clear and thick.Recurrent respiratory tract infection is very
common which can cause fever, dyspnea, production of purulent
(cloudy and discolored) sputum and wheezing. Infections occur
more frequently as bronchitis  progresses.
3. Symptoms due to advanced COPD symptoms
?  cyanosis may develop
?  Headaches, clouding of consciousness, altered behaviour
due to retention of  carbon dioxide in  blood.
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? Weight loss occurs  because it is a chronic inflammatory
state  and  there  is  additional  energy  that  is  required  to
breathe.
? In advanced COPD, there is destruction of gas-exchanging
air spaces in the lungs and this blocks the flow of blood
through the lungs. As a result, the pressure in the
pulmonary artery increases resulting in  pulmonary
hypertension. This results in development of  right heart
failure also known as Cor pulmonale .
? Patients with COPD may cough up blood (hemoptysis).
Usually hemoptysis is due to damage to the inner lining of
airway blood vessels;
12
PATHOPHYSIOLOGY OF COPD
Neergard and Wirz in 1927was the first to show expiratory
airway resistance. Some studies from corbin  showed  increased static
lung volumes (RV, FRC, and TLC), in people who were chronic
smokers.
COPD pathophysiology is not completely understood.  Major
role is that of chronic inflammation of the cells which line the bronchial
tree. Smoking, and other airway irritants, increases the ongoing
inflammatory response which leads to hyperactivity of the airways,
whereby the smooth muscle of the airways constrict and narrow
excessively.  Airways  become swollen, excess mucus is produced and
the cilia  to function poorly which leads to pooling of the airways with
mucus.
As  excess mucus is produced, it begins to pool in the airways,
providing a  breeding ground for bacteria to multiply. This leads to
further inflammation, in the bronchial tree and bacterial infections which
occur frequently in COPD patient.
A new hypothesis for the beginning of COPD, that the immune
response to inhaled agents, mainly cigarette smoke, is directed toward
13
the  epithelium  of  airway,  due  to  oxidative  DNA  damage  of  the  lung
epithelial barrier cells (LEBCs).
The steps of this model are as follows.
 1)  Cigarette smoke causing oxidative DNA damage to LEBC.
2)  The acquired mutations of Lung epithelial barrier cells
(LEBCs) are expressed  at the microsatellite DNA level.
 3)   Dendritic cells (DCs) recognize the altered LEBCs as
“foriegn”. Dendritic cells  travel to the lymph nodes,and then it
presents it  to the naïve T-lymphocytes.
4)  There is a predominant CD8+ cytotoxic T-lymphocyte
proliferation. The CD8+ cells, release perforin and granzymes,
which attack the altered LEBCs activating cell death cascade.
STUDIES SUPPORTING THIS HYPOTHESIS
Oxidative DNA damage of LEBCs in COPD
There are number of different defense mechanisms against
noxious or infectious agents in the respiratory tract. In the airways, the
first line of defence the  constitutes the LEBCs and have been shown to
differ in number and function in smoke-related diseases  such as
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COPD (23–25). Oxidative stress is believed to be a central component in
COPD pathogenesis as smokers are exposed to thousands of radicals and
reactive chemicals with every cigarette,. ROS, reactive nitrogen species
(RNS) and carbon-centred radicals are the major constituents  of smoke .
Also endogenous sources of ROS, such as those produced by activated
alveolar macrophages and neutrophils in response to smoke, cause
further  epithelial cell damage . Increased ROS production is linked to
oxidation of proteins and DNA  which may cause direct lung injury or
induce a variety of cellular responses. ROS can cause damage to nucleic
acids, resulting in base modifications,  strand breaks, mismatches and
cross-links, leading to increased levels of somatic mutation .  These
mutations are supposed to be corrected by endogenous repair processes,
such as the human DNA MMR system. However, post-translational
inactivation of repair enzymes by free radicals may cause the
accumulation of damaged DNA .
The oxidative burden of smoking damages the DNA of lung
epithelial barrier cells (LEBCs) and inactivates the human DNA
mismatch repair system, leading to acquired somatic mutations of
LEBCs. Altered LEBCs are recognised as ‘‘nonself’’by the host,
15
inducing an abnormal immune response towards the altered LEBCs,
resulting in the activation of cell death cascades.
Figure 1. The proposed  model for the beginning of  COPD. Cigarette smoke causing oxidative DNA
damage to LEBC and inactivates the human DNA mismatch repair system, leading to acquired
somatic mutations of LEBCs. Altered LEBCs are recognized as “foreign” by the host, inducing an
abnormal immune response towards the altered LEBCs. This results in the activation of cell death
cascades.
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Interestingly, female smokers have accelerated metabolism of
cigarette smoke leading to increased burden of DNA adducts (25, 26) and
hence  are more susceptible to somatic mutations, which may predispose
to COPD (25, 26.)
Acquired somatic mutations of  LEBCs
Molecular damage in the lung epithelium is present even after
smoking cessation. Microsatellite DNA instability has been found in
sputum cells of COPD patients28.  Studies have shown microsatellite
instability exclusively in the sputum epithelial cell
subpopulation 28, isolated by immunomagnetic separation.
The  MMR  system  is  a  DNA  repair  mechanism  known  to  be
very effective at identifying and subsequently rectifying errors in DNA
replication.  The MMR corrects base substitutions and frameshift errors.
It has been demonstrated that oxidative stress associated with cigarette
smoke and chronic inflammation might damage protein components of
the MMR system, leading to its functional inactivation 28, . Moreover,
Makris et al. 29 showed a significant association between microsatellite
DNA instability and COPD exacerbations, indicating a link between
altered DNA MMR system and oxidative DNA damage due to frequent
COPD exacerbations or vice versa 29.
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Host immune response to the altered LEBCs:
There are many types of cell damage which leads to DNA
fragmentation and destruction of the repair potential that allow its
recognition as “foreign” 30, 31.,
Figure 2. Acquired somatic mutations of lung epithelial barrier cells (LEBCs) in chronic obstructive
pulmonary disease (COPD).
In  this  theory   it  is  thought  that  once  the  LEBCs  suffer
oxidative DNA damage they are detected as “nonself” by the  Dendritic
Cells 32.
After  sampling of antigen in the periphery, DCs migrate  to
regional lymph nodes, where they activate naïve T-cells 33.Studies show
that it is highly likely that DCs are implicated in the pathogenesis of
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COPD, not only in the initiation but also in the perpetuation of chronic
airway inflammation 34, 35, 36.   DCs interact with naïve lymphocytes to
induce one of three predominant responses: T-helper cell (Th) type 1,
Th2 or T-regulatory 37.
INDUCTION  OF  A  PREDOMINANTLY  CD8+ CYTOTOXIC
TYPE I  T-    LYMPHOCYTE PROLIFERATION:
It has been proven that, in COPD, DCs help in the induction of
a predominantly CD8+ cytotoxic type I T-lymphocyte response 38, 39, .
This causes chronic airway inflammation with increased numbers of
CD8+ cells  and release of  IFN inducible protein 10,  IFN-? and tumour
necrosis factor (TNF)-?, as well as perforin and granzymes 40, 39, .
CD8+  cells  attack the altered LEBCs and perform cytotoxic
functions, activating cell death cascades41, 42, 43.  In  agreement  with  this,
Chrysofakis et al. 43showed that CD8+ T-cells from patients with COPD
produced more perforin and were extremely cytotoxic. Perforin-
dependent events leads  to   apoptosis.Apoptosis, is anti-inflammatory in
nature,  but  if  the  apoptotic  bodies  are  not  removed  in  time  leads  to
persistent inflammation .
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MMP-12 in Smoking-Related COPD
Cigarette smoking  is the major risk factor for both chronic
bronchitis and emphysema. .46Inflammation, proteinase imbalance,
oxidative stress, all appear to be involved in the pathogenesis of COPD
and the matrix metalloproteinase 12 (MMP-12) plays a role in every of
these processes (Figure 3).
Usually there is  an   innate  balance in the body between the
protective  factors  like protease inhibitors , elastase inhibitors   and
harmful factors like proteases ,elastases ; when  the  normal milieu of
this   balance   is   disrupted   by   external  factors   which  may  include
infection , undue  inflammatory stimulation then  there will continuous
damage to the  viscera ;  Chronic  obstructive  pulmonary  disease  can
be   explained   in   part   by   this   mechanism   too 47 ;This protease-
antiprotease imbalance is now assumed be due to inflammation which is
chronic .47Macrophage elastase MMP-12 (inhibited by TIMP-1) and
neutrophil elastase (inhibited by alpha-1-antitrypsin) are the most
common elastases found  in the lung. TNF alpha, is the major recruiter
of  neutrophils  to  the  lung  that  is  released  from  the  cell  membrane  by
MMP-12, ; IFN-gamma also recruits neutrophils and stimulates MMP-
12 activity.47,48,49
One  more  molecule  which   also  recruits  neutrophils  and
stimulates MMP-12 activity is IFN Gamma.47,48,49 These neutrophil
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elastases and oxidants secreted in the environment with inflammation
mediate much of the destruction of lung tissue.50Elastin fragments itself
are chemotactic, which  recruits monocytes.  Some of these
differentiates to form alveolar macrophages that is composed of  bulk of
the inflammatory cells accumulating in the alveolar airspaces and
interstitium in emphysema.51
Figure 3. MMP-12 is produced by alveolar macrophages, smooth muscle cells, and epithelia in
response to cigarette smoke. It is a key molecule in the recruitment of inflammatory cells, release of
TNF-alpha, and pathways downstream of TGF-beta activation. These activities lead to the airway
damage, fibrogenesis, repair, and remodeling that are the hallmarks of COPD.
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One more important thing supporting this hypothesis is the fact
that  increased  levels  of  MMP-12  is  seen  in  sputum  of  patients  with
COPD. Also some experiments in mouse have shown that MMP-12
deletion stops the development of smoking induced COPD. Several
other studies have shown that neutrophil elastase inhibition significantly
reduces lung damage. Hence  deficiency of human alpha-1-antitrypsin,
which is a  inhibitor of human neutrophil elastase, leads to susceptibility
to COPD.
TREATMENT OF COPD
The  first   important   thing   in   treating  chronic    obstructive
pulmonary disease is  to  understand  the   reality  that  this  is  a  disease
which   cannot   be   cured  but   can  only   be   kept  under  control   if
appropriate  lifestyle  changes  and adherence  to  both the  medication
and  health  advice  is  strictly  followed ;
The  main aim in treatment of COPD include:
? slowing the  decline in lung function;
? relieving symptoms, such as dyspnea and cough;
? decreasing exacerbations
? improving quality of life
22
SMOKING CESSATION
Among  the  many   factors   which   add   to   the   damage
inflicted  by  COPD, the  prime  one  is  smoking ; putting   an  end   to
this   health  hazaerd  goes  a   long  way  in  curtailing  the  morbidity
and  mortality  of  COPD ; `
The most important step is encouraging smoking cessation.
Smoking is directly  related to  loss of lung function . Even in advanced
disease  patient   can  benefit  from  smoking  cessation.   It  also  stops  the
loss of lung function in younger patients with relatively mild disease.
This may be aided by the use of  nicotine replacement therapy
(by gum,transdermal patch or inhaler) or bupropion ,a noradrenergic
antidepressant. Bupropion has been shown to be quite effective in this
regard .
TREATMENT OF RESPIRATORY INFECTIONS
Purulent sputum is treated with oral tetracycline or ampicillin
250 mg 6 hours  or cotrimoxazole 960 mg 12 hourly for 10 days.
In the absence of response, a sputum culture and sensitivity is
done and the antibiotic changed accordingly.
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BRONCHODILATOR THERAPY AND STEROID THERAPY
BETA 2  ADRENORECEPTOR ANTAGONISTS:
? Inhalation of beta2- adrenoreceptor agonists like salbutamol
200 mcg or terbutaline 500 mcg 6 hourly,in mild to
moderate disease.
? These agents are short-acting and needed to be taken
frequently. Long –acting beta-stimulants(salmeterol and
formoterol) are the preferred agents for achieving
bronchodilation.
? These agents may reduce the incidence of infective
exacerbations since these drugs reduce the adhesion of
bacteria to airway epithelial cells.
ANTICHOLINERGICS:
Anticholinergic drugs, form one of the important part of the
treatment schedule in decreasing the frequency and severity of COPD
exacerbations. Some of the examples are ipratropium bromide,
thiotropium bromide. They act by decreasing the secretion of mucus in
response to the inflammatory onslaught and also significantly causes
symptomatic improvement.
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Despite these advantages, they seem to play not much of a role
in  the  emergency  room,  as  they  seem  to  be  of  more  benefit  in
modulating the disease course in the long run if used regularly.
CORTICOSTEROIDS:
Basically COPD is a inflammatory disease and it was widely
believed that steroids would be the  ultimate therapy . Despite the  initial
hope  they  generated  steroids  seem  to  play  not  much  of  a  role  in  the
management of COPD as compared to bronchial asthma.
Hence, inhaled corticosteroids are not indicated for the treatment
of COPD. They  have a limited role  in patients with COPD. Only about 10
percent of patients with COPD show a significant improvement . The
reason is that different mediators cause inflammation in asthma and
COPD. Oral theophylline in seleced cases.
25
PULMONARY REHABILITATION
The various techniques of physical therapy (upper extremity
exercises, controlled breathing techniques), targeting the training of
respiratory muscles in patients with COPD.
Intermittent mechanical ventilation in stable COPD stages, to
rest inspiratory muscles.
OXYGEN THERAPY
1. Controlled oxygen therapy,
A  flow  of  2-4  liters  /  min  is  satisfactory,  mask  or  nasal  tube
can be used (15 to 20 minutes, with intermission).
2. Long-term oxygen therapy has the benefit of the reversal of
Pulmonary hypertension.
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GOLD Spirometric Criteria for COPD Severity
I. Mild
COPD
*  FEV1/FVC < 0.7
*   FEV1  >  or  =  80%
predicted
At  this  stage,  the  patient  is
probably unaware that lung
function is starting to
decline
II.
Moderate
COPD
*  FEV1/FVC < 0.7
* FEV1 50% to 79%
predicted
Symptoms during this stage
progress, with shortness of
breath developing upon
exertion.
III.
Severe
COPD
*  FEV1/FVC < 0.7
* FEV1 30% to 49%
predicted
Shortness of breath becomes
worse  at  this  stage  and
COPD exacerbations are
common.
IV. Very
Severe
COPD
*  FEV1/FVC < 0.7
* FEV1 < 30% predicted or
FEV1 < 50% predicted with
chronic respiratory failure
Quality of life at this stage
is gravely impaired. COPD
exacerbations can be life
threatening.
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LIMITATIONS OF THIS CLASSIFICATION
FEV1 is very important for diagnosis and assessing severity of
the disease. FEV1 is a good marker of disease progression and mortality
but FEV1 does not correlate well with the degree of dyspnea44, and the
change in FEV1 does not reflect the rate of decline in patients' health45.
As COPD is  a  multisystem disorder  FEV1 alone cannot determine the
outcome in these patients.
Hence a multidimensional grading system was designed which
included four variables body-mass index (B), the   degree of airflow
obstruction (O) and dyspnea (D), and exercise capacity (E) measured by
the six-minute–walk test.  Each of these correlates   directly with the
prognosis.
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MATERIALS AND METHODS
INSTITUTIONAL ETHICS COMMITTEE APPROVAL
Obtained
STUDY DESIGN
• Place:    Govt. Stanley Hospital
• Study Design:    Observational  Study
Period  of  study : April 2011 to June 2011 ;
SAMPLE SIZE
• Cases : 100
INCLUSION CRITERIA
? A  FEV1 of  less than 15% from the baseline value  measured 2o
minutes after  the administration of    salbutamol with  significant
symptoms.
EXCLUSION CRITERIA
• Comorbid conditions  previously detected CCF or UA,
Myocardial infarction within the preceeding 4 months.
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• An inability to take the lung function test and six minute walk
tests.
• Asthma defined as an increase in FEV1 of more than 15% above
the baseline value or of 200ml after administration of
bronchodialator.
• Patients with TB,Bronchiectasis or any other parenchymal lung
disease.
STUDY  METHODOLOGY
All the patients who attend medicine opd and chest clinic opd
will be screened acoording to the inclusion exclusion criteria and those
patients who satisfy the criteria and give consent will be enrolled. For
each  subject- smoking, personal , occupational histories were obtained.
Height and weight were also measured during the examination. Weight
was measured by a weighing machine.
Height was measured in “mm” with the stadometer. Body
mass index (BMI) was   calculated  using the formula.
                BMI = Weight in Kgs / (Height in Ms)2
After clinical examination they will be subjected to PFT using
a spirometer. Spirometry  is   performed  using  a  portable  spirometer
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(SpiroPro;  Erich Jaeger GmbH; Hoechberg,  Germany) according to the
American Thoracic society.
Using a Spirometer  patient is asked to inhale deeply, after all
air has
been expelled.  After this maneuver patient is asked to rapidly exhale so
that all the air is exhausted from the lungs.Results of spirometry tests
vary, but are based on predicted values of a standardized, healthy
population. FEV1 and FVC was obtained . %FEV1 was obtained. An
average of three readings were taken. A   history  of  the  dyspnea
experienced by the patient was taken. MMRC(Modified medical
research council) dyspnea scale was used to score the patients dyspnea.
MMRC dyspnea scale
Grade 0 – no dyspnea / only on severe exertion.
Grade 1 – dyspnea on hurrying / walking up a hill.
Grade  2  –  walks  slower  than  normal  at  level/  pause  while  walking  on
level ground.
Grade 3 – stops for breath after walking 100 yards/few mins on level
ground.
Grade 4 – too breathless to leave the house/ dyspnea on dressing.
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The  best  of  two  6-min  walk  tests  performed  at  least  30-min
apart was used for scoring.  On  a  level  ground  patient  were  asked  to
walk  for maximum possible distance within a duration of 6 minutes. If
rest was taken in between then periods of rest  were also included in the
6 minutes test period .
The BODE index was calculated for each patient using the
body mass index, the threshold value of FEV1, the distance walked in 6
min, and the score on the modified Medical Research Council (MMRC)
dyspnea scale .Each variable is   given a point  .  Each subject  is  given a
BODE score out of 10.Using appropriate statistical tests correlation and
the  strength  of  correlation  will  be  computed  between  the  severity  of
BODE  INDEX,  Pulmonary  hypertension  ,  risk  of  readmission  and
whether bode index can be downsized by rehabilitation.
Pulmonary hypertension is graded by TRPG (transtricuspid
pressure gradient)based on ECHO.
• MILD – 30 to 45mmHg
• MODERATE – 45 to 70mmHg
• SEVERE- MORE THAN 70 mmHg
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Patients were asked to undergo regular cardiopulmonary
rehabitilation. They were also advised to take regular bronchodialators.
After  6 months patients BODE index was calculated  again.The number
of times patients were admitted was checked using their discharge
summaries.  ECHO  was  done  again  and  the  severity  of  pulmonary
hypertension determined.
BODE INDEX
BODE score 0 1 2 3
FEV1 >/= 65 % 50 – 64% 36 – 49%
< /=
35%
6 min walk
Test
>350 ms 250 – 349ms 150 – 249 ms
<149 ms
Dyspnea
Scale
0 – 1 2 3 4
BMI > 21 kg/m2 <21 kg/m2
Mild COPD ? 0 – 2
Moderate COPD ? 3 – 5
Severe COPD ? >/= 6
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STATISTICAL ANALYSIS
After catergorizing the variables statistical analysis was done
in 100 patients. Baseline data was collected from patients without and
with mild, moderate and severe COPD. Ages, FEV1, number of
admissions, pulmonary hypertension, of all subjects were the parameters
analyzed.
The significance of difference in means between two groups was
analyzed using the one way ANOVA F-test and the significance of
difference in proportions by the Chi square test. Statistical significance
was taken when the p-value was less than 0.05.
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Table 1: BASELINE PARAMETERS OF THE STUDY
POPULATION
The above table enumerates the various parameters of the
study population and their statistical mean, minimum value maximum
value with standard deviation
Table 2 : SEX  AND AGE DISTRIBUTION
SEX FREQUENCY PERCENT
MALE 23 23.00
FEMALE 77 77.00
TOTAL 100 100.00
Descriptive Statistics
100 30.00 85.00 52.5800 10.19624
100 44.00 70.00 53.4700 5.39070
100 1.30 1.72 1.5212 .09753
100 16.90 31.80 23.1930 3.26224
100 14.00 22.00 17.7000 2.43916
100 22.00 66.00 50.0100 11.68915
100 89.00 99.00 97.8300 2.14643
100 18.00 76.00 38.4100 15.72561
100 .00 9.00 4.2100 2.44245
100 .00 8.00 3.5100 2.12486
100 15.00 66.00 48.3300 13.26502
100 18.00 79.00 40.0200 16.68301
AGE
WT
HT
BMI
RRATE
FEVIPER
SPO2
TRPG
BODEINDE
PIBODE
PIFEV1
PITRPG
N Minimum Maximum Mean Std. Deviation
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Table 2 (a) . AGE GROUP
AGE GROUP FREQUENCY PERCENTAGE
30 – 40 14 14.00
41 -50 34 34.00
51 – 60 33 33.00
61 – 70 16 16.00
> 70 3 3.00
TOTAL 100 100
AGE GROUP FEMALE MALE PERCENT
30 – 40 17.4 (  4 ) 13.0 ( 10 ) 14.00
41 -50 30.4 ( 7 ) 35.1 ( 27 ) 34.00
51 – 60 34.8 ( 8 ) 32.5 ( 25 ) 33.00
61 – 70 8.7 ( 2 ) 18.2 ( 14 ) 16.00
> 70 8.7 ( 2 ) 1.3 ( 1 ) 3.00
TOTAL 100 100 100
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Out of the 100 patients 77 were males and 33 were females.
In  the age group of (30-40) there were 14% of patients,( 40 – 50) there
were 34% of patients ,(50-60) there were 33% of patients,(60-70) there
were 16% of patients and more than 70 there were 3% of patients.COPD
is more common in middle aged people even though it did not reach
statistical significance.
Table 3 .BODE SCORE & SEVERITY OF  PHT
PHT NUMBER MEAN MIN MAX. ST.DEV.
ABSENT 43 2.0233 .00 4 0.83062
MILD 35 4.8000 2.00 8 1.41005
MOD. 16 7.120 5.00 9 1.4746
SEVERE 6 8.667 8.00 9 0.5164
TOTAL 100 4.2100 0.00 9 2.4424
         p < 0.001 hs
37
Out of the 100 patients 43 did not have pulmonary
hypertension and their mean bode score was 2.0233. 6  patients   had
severe  pulmonary  hypertension(Mean BODE SCORE 8.667) ; 16 had
moderate  PHT,(mean  BODE  SCORE   7.120)and  35   had   mild  PHT  ;
according to  our study the association  between  severity  of  pulmonary
hypertension   and  high  BODE  score  was   statistically    significant   as
shown  by  the  p value  < .001.
Table 5: COPD Vs BODE INDEX
No Mean
Standard
Deviation Minimum Maximum
MILD 37 1.729 0.508 0.00 2.00
MODERATE 37 4.297 0.845 3.00 5.00
SEVERE 26 7.615 1.022 6.00 9.00
As the degree of COPD increases the mean bode score
increases. People with mild COPD had mean bode score of 1.72 and
severe COPD  had a mean bode score of 7.6154.This is statistically
highly significant as (p < .001)
38
Table 6 : ADMISSION Vs BODE INDEX
ADMISSION N MEAN
STD.
DEV
MIN MAX
0.0 53 2.5283 1.6005 0.00 8
1.0 30 5.133 1.11658 2.00 8
2.0 8 7.3750 1.40789 5.00 9
3.0 9 8.2222 0.66667 7.00 9
In  our  study  of  the  30  patients  who  got  admitted  once  had  a
mean BODE score of  5.133. 8 patients got admitted twice had a mean
BODE score of 7.3750. 9 patients got admitted thrice had a mean bode
score of 8.2222. This is statistically highly significant(p< .001).Hence as
the BODE index increases the number of readmissions are more.
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Table 7 :     DEGREE OF COPD vs  NO OF ADMISSIONS
COPD
NUMBER OF ADMISSIONS
0.0 1.0 2.0 3.0 TOTAL
MILD 36 1 0 0 37
MODERATE 14 22 1 0 37
SEVERE 3 7 7 9 26
TOTAL 53 30 8 9 100
p<0.001
Out  of  the  100  ,  37  patients  had  mild  COPD  .  They  were
admitted  only  once  in  the  course  of  our  study  ;among   those  who  had
severe COPD , i . e  26 of them ,  9 were readmitted thrice , and 8 were
admitted twice ; as the severity increased the number of readmissions
increased as shown by the p value <0.001 which is a statistically
significant
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Table 8 : SEVERITY OF PHT & NUMBER OF ADMISSIONS
PHT
NUMBER OF ADMISSIONS
0.0 1.0 2.0 3.0 TOTAL
ABSENT 43 0 0 0 43
MILD 8 27 0 0 35
MODERATE 2 3 7 4 16
SEVERE 0 0 1 5 6
In  our  study  out  of  the  35  patients  with  mild  pulmonary
hypertension 27 got admitted once.16 patients with moderate pulmonary
hypertension 3 got admitted once,7 got admitted twice and 4 got
admitted thrice.6 patients with severe pulmonary hypertension 1 got
admitted once and the rest 5 three times.Statistically this was highly
significant as the p value is< 0.001.  As the pulmonary hypertension
increased the  rate of readmission also increased.
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Table 9 : PRE AND POST INTERVENTION STATISTICS ;
VARIABLE N MEAN STD.DEVIATION
STD.ERROR
MEAN
FEV1 100 50.0100 11.68915 1.16892
BODE 100 4.2100 2.44245 .24424
TRPG 100 38.4100 15.72561 1.57256
Table 10 .POST INTERVENTION PARAMETERS
VARIABLE N MEAN STD.DEVIATION
STD.ERROR
MEAN
P.I FEV1 100 48.300 13.2652 1.32650
P.I BODE 100 3.5100 2.12482 .21249
P.I TRPG 100 40.0200 16.6830 1.66830
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Table 11 . PAIRED SAMPLE TEST
PAIRED DIFFRENCE
T p
MEAN STD.DEV
FEV1 – PIFV1 1.6800 2.0259 7.616 <0.001
BODEINDE – PIBODE 0.7000 0.62765 11.153 <0.001
TRPG - PITRPG -1.6100 1.91166 -8.422 <0.001
In our study we found out that the mean Bode reduced from
4.2 to 3.51 following intervention. But the mean TRPG continued to
increase despite interventions
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DISCUSSION
COPD(Chronic obstructive pulmonary disease) is disorder
which leads to significant mortality and morbidity. BODE index is a
multidimensional grading system which predicts mortality better than
FEV1. This multistage scoring system which includes an assessment of
symptoms, nutritional state, and exercise capacity along with the
spirometric measure of airflow (FEV1) can provide useful prognostic
information in patients with COPD.
Men are much more likely to be diagnosed with COPD then
women, though the prevalence in women is on a steady raise 11.Even in
our study males had a greater preponderance with 77% of them having
COPD.In  our  study  we  found  out  that  the  prevalence   of   the   disease
increased  with  age  more   than  40  ,  though  statistically  it  was  not
significant ; The results are similar to a study conducted by N.S. Zhong,
P.X. Ran in China. Every 1 in 10 patients over the age of 40 years had
COPD.
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BODE INDEX & SEVERITY OF PULMONARY
HYPERTENSION
10   -  30  %   of   patients   with  COPD  develop  pulmonary
hypertension52 ;  Out of the 100 patients 57  developed  pulmonary
hypertension  ; 43 did not develop pulmonary  hypertension ;those  who
did   not   develop   PHT  had   a   mean   BODE   score  of  2.0233.   6
patients   had severe  pulmonary  hypertension(Mean BODE SCORE
8.1) ; 16 had  moderate PHT,(mean BODE SCORE  7.120)and 35  had
mild PHT ;   according to  our study the association  between  severity
of   pulmonary   hypertension   and  high  BODE  score  was   statistically
significant   as  shown   by   the   p  value   <  .001.  Pulmonary  HTN  is
caused due to hypoxic vasoconstriction, increase in lung
volume,acidosis and secondary polycythemia.
COPD SEVERITY AND BODE SCORE
Total of 37 patients each were found in the mild and moderate
COPD group;26 patients were found to have severe COPD. The mild
and moderate group had a mean BODE score of 1.72 and 4.29
respectively.The severe COPD group had a mean BODE score of
7.6154.This was found to be statistically significant p<0.001
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BODE SCORE AND NO. OF READMISSIONS
According to studies from  Kian-Chung etal  has proven that
BODE scores  correlates well with severity in terms of hospitalization
and mortality. In a developing  country where the health care resources
are sparce BODE scoring system may  be very helpful in health-care
resource allocation and in guiding therapy for individual patients in the
future.
Some studies showed a single BODE index assessment is
enough to predict survival and hospital readmissions over 3 years in
patients with chronic obstructive pulmonary disease
(COPD). According to a study done by David Hui, a change in BODE
index score of more than one point between baseline and 6 month
assessment was marginally predictive of mortality, but serial changes in
BODE index between the other time-points were not predictive of
mortality.However, serial increases in BODE index of at least one point
at 6, 12 and 24 months, were predictive of earlier readmissions to
hospital. A single measurement of BODE index could predict mortality
and  readmissions  over  time.  Ong  et  al,  2005(53) who found
hospitalization and mortality in COPD patients higher with low 6m walk
test.  Also Celli et al, 2004(4) found that risk of death in
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COPD patients was more with low 6min walk score.
In a study done by Adel Khattab, Khaled Wagih, Ahmed
Mohamed  by using BODE index as a predictor of risk of hospitalization
in COPD patients, the results were statistically highly significant,
indicated that risk of hospitalization increases by increasing BODE
score.  In our study we found  that.  8 patients  got  admitted twice had a
mean BODE score of 7.3750. 9 patients got admitted thrice had a mean
bode score of 8.2222. This was statistically highly significant (p<
.001).Hence as the BODE index increases the number of readmissions
are more.
This was fully fit with Ong et al, 2005(53) study they used BODE index
as predictor of hospitalization in COPD patients and compared it with
FEV1classification of  GOLD and found that  BODE index was a better
predictor of hospitalization than using FEV1 alone. As  patients with
higher BODE scores had higher rates of hospitalization.
DOWNSIZING OF BODE SCORE FOLLOWING
INTERVENTION
A observational study done by C.G. COTE AND B.R. CELLI
over  one  year  in  patients  with  COPD  showed  that,  the  response  to
Pulmonary Rehabitilation(PR) can be objectively measured using the
BODE index and the change in BODE index provides information
regarding ultimate survival.
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Also, participation in a rehabilitation  programme  is
associated  with  a  decrease in hospitalizations. Rehabitilation has
minimal effects on lung function but it improves dyspnea ,exercise
capacity and health status.
According to Celli et tal (53) exercise capacity is a prognostic
marker. The current authors defined one unit change in BODE as being
clinically significant because it implies a change in any of its component
of a magnitude large enough to influence clinical outcomes. This study
also documented improvement in healthcare resources among these
patients.
In our patients following interventions the mean BODE
SCORE reduced from 4.21 to 3.51 which is a significant reduction in 6
months. The FEV1 levels came down indicating decrease in lung
function despite therapy. The TRPG values increased mildly indicating
increasing PHT. Though COPD is a progressive disease, an assessment
of  the post treatment improvement  can be done and it has been
demonstrated conclusively by the above studies. The BODE score,
which is a composite marker of COPD severity, has been shown to
decline significantly on treatment despite the contradictory evidence of
the progression of the basic disease problem per se.
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LIMITATIONS OF THE STUDY
1. This study includes local  population and hence it  is unlikely
to represent  the  population  all over the  world.
2. The environmental factors thatplay a role in COPD differs
from population to population, counrty to country which
prevents us  from generalizing the results to wider population.
3. The  sample  size  was  relatively  small,  to  be  able  to  give  an
unchallengeable  statistically significant hypothesis.
4. The compliance of the  patients is variable which could affect
the study results especially the  post intervention parameters.
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SUMMARY AND CONCLUSIONS
In our study comprising hundred patients of COPD ,
conducted in government Stanley medical college ,we had compared
BODE score with various parameters and analysed it statistically and
got the following results ; Summarising
? BODE score was much better in predicting the morbidityand
mortality associated with COPD than FEV1;
? Males  were  predominantly  affected  by  COPD  in  our  study  ;
this was in concordance with other similar  studies ;
? The prevalence of COPD increased with age in our study and
the association was statistically significant ;
? Maximum  number  of  COPD  patients   occurred  in  the  age
group 50 – 60 years in our study ;
? BODE score   correlated  with  the  severity  of  COPD and  PHT
and this correlation was statistically significant in our study .
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? Higher the BODE  score, frequent the number of readmissions.
? BODE score is amenable to modification with appropriate
medical intervention and thus can be used to assess therapeutic
efficiency ;
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CONCLUSIONS
1. BODE score correlates with severity of pulmonary hypertension
and COPD.
2. BODE score can predict  the number of readmissions in COPD
patients;
3. BODE  score   can  be  inproved  by  adequate  and  timely
therapeutic intervention and rehabilitative measures ;
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ABBREVIATIONS
ERS - European Respiratory Society
COPD - Chronic obstructive pulmonary disease
RV - Residual volume
PHT - Pulmonary hypertension
TLV - Total lung volume
FEV1 - Forced expiratory volume in 1 sec
PI FEV1 - Post intervention FEV1
IFN - Interferon
CD 8 - Cluster of differentiation
MMP - Matrix metalloproteinases

PROFORMA
S.No :
Date :
Name :
Age :
Sex : F/M
Address :
PRESENTING COMPLANTS :
Cough with Expectoration :
Pedal edema :
Breathlessness :
Chest pain / Palpitation :
Past history :
DM / HT / IHD / CKD / COPD :
Personal history :
Family history :
Occupational history :
Examination :
Pulse :
BP :
JVP :
R.R :
HT :
WT :
BMI :
CVS :
RS :
Investigations :
CBC :
Sugar :
Urea :
Creatinine :
PFT Reversibility :
Resting SPO2 :
Xray Chest :
ECG :
ECHO :
Initial Admission :
Provisional Diagnosis :
Pre Treatment : Post Treatment
BODE INDEX
FEV1
ECHO
NAME AGE SEX WT HT     BMI  R.R %FEV1 Sp O2 PHT TRPG BODE COPD ADM P I BODE P I % FEV1 P I TRPG 
SUBBURAJ 42 M 50 1.6 19.5 21 51% 94% moderate 48 6 severe 1 5 46% 51 
UNNAMMAL         48 F 60 1.5 26.66 18 65% 99% absent 30 0 mild 0 0 65% 30 
PRABAKAR            52 M 55 1.45 26.15 16 55% 99% mild 32 2 mild 0 2 52% 35 
THANIKACHALAM   51 M 48 1.5 21.33 17 60% 99% absent 28 2 mild 0 1 60% 28 
AMUDAN 56 M 53 1.45 25.21 18 63% 98% absent 26 4 moderate 0 3 63% 26 
MUNIYAMMAL       49 F 58 1.39 30.05 16 54% 99% Absent 24 3 moderate 0 2 54% 24 
SHARADA                52 F 46 1.5 20.44 18 53% 98% mild 38 5 moderate 0 4 52% 44 
SUSHELA 49 F 48 1.48 21.9 17 57% 98% mild 42 3 moderate 0 3 55% 42 
PADMA 55 F 52 1.4 26.53 15 55% 98% mild 33 3 moderate 0 3 53% 37 
KANNNAN                50 M 55 1.55 22.87 16 44% 96% moderate 55 7 severe 2 6 39% 58 
SURAJ 49 M 49 1.54 20.66 14 59% 99% mild 36 4 moderate 1 3 56% 36 
RAJAN 51 M 50 1.5 22.22 22 60% 99% mild 44 5 moderate 1 4 59% 49 
KARTIKEYAN              57 M 49 1.52 21.2 17 54% 99% mild 41 4 moderate 1 4 52% 44 
SRIDHAR 58 M 56 1.4 28.57 14 53% 99% absent 26 2 mild 0 2 53% 26 
SUNDAR 62 M 60 1.58 24.03 14 34% 95% moderate 60 8 severe 3 7 30% 64 
SANTOSH 50 M 51 1.6 22.6 19 55% 99% mild 41 5 moderate 1 4 54% 45 
JAMES 40 M 49 1.39 25.36 16 53% 99% mild 38 3 moderate 0 3 52% 43 
SUBRAMANI 70 M 50 1.55 20.8 18 39% 97% moderate 60 7 severe 0 6 34% 60 
MANIKANTHAN 46 M 46 1.46 21.4 19 40% 99% mild 33 8 severe 0 6 40% 38 
GOPALAKRISHNAN 50 M 56 1.6 21.8 22 48% 99% mild 42 5 moderate 1 4 45% 46 
SUKUMAR 38 M 49 1.7 16.9 18 60% 97% moderate 64 8 severe 0 7 55% 67 
CHINNARAJ 61 M 59 1.5 26.22 17 63% 99% absent 26 3 moderate 0 2 63% 26 
DHARMAR 60 M 60 1.72 20.28 16 59% 99% absent 25 3 moderate 0 3 59% 25 
DEVAN 60 M 51 1.7 17.64 17 48% 99% mild 36 6 severe 1 5 47% 36 
RAMESH 42 M 47 1.5 20.8 18 55% 99% absent 25 4 moderate 0 3 55% 25 
PERUMAL 85 M 50 1.41 25.15 15 44% 99% mild 39 5 moderate 1 5 43% 43 
MURUGA 38 M 60 1.7 20.7 14 55% 99% absent 30 3 moderate 0 3 55% 30 
ELANGO 62 M 47 1.42 23.37 20 58% 99% absent 27 4 moderate 0 3 58% 27 
ASHWIN 42 M 44 1.5 19.55 16 50% 99% mild 44 5 moderate 1 4 48% 48 
NAVEEN 45 M 49 1.46 22.99 18 40% 96% moderate 55 7 severe 2 6 35% 57 
RAJENDRAN 38 M 67 1.5 25.33 21 30% 90% severe 75 9 severe 3 7 24% 79 
VENKATESH 53 M 54 1.62 20.59 19 58% 99% absent 29 2 mild 0 2 58% 29 
SHANTHAKUMAR 55 M 56 1.61 21.8 22 62% 99% absent 22 2 mild 0 1 62% 22 
JAYAPAL 50 M 56 1.7 19.3 15 60% 99% absent 28 3 moderate 0 2 60% 28 
CHELLAYA 60 M 46 1.48 21.4 17 45% 99% mild 39 5 moderate 1 4 43% 43 
SAGARAJ 47 M 60 1.54 25.6 19 55% 99% mild 41 4 moderate 1 3 54% 44 
ABDUL 65 M 56 1.5 24.88 20 52% 99% absent 26 2 mild 0 2 52% 26 
JOHN 67 M 54 1.6 21.09 21 38% 97% moderate 60 7 severe 3 6 34% 64 
TIRUPATHI 30 M 56 1.62 21.34 22 63% 99% absent 27 1 mild 0 1 63% 27 
SHAKTIVEL 35 M 47 1.5 20.88 14 61% 99% absent 23 2 mild 0 2 61% 23 
WILLIAMSON 45 M 45 1.4 22.95 19 58% 99% absent 19 1 mild 0 1 58% 19 
BALAJI 45 M 61 1.51 26.75 17 42% 99% mild 35 5 moderate 1 4 41% 39 
LOGANATHAN 39 M 50 1.6 19.5 15 52% 98% mild 43 6 severe 1 5 51% 47 
BHAVANI 45 F 60 1.5 26.66 20 58% 97% absent 27 2 mild 0 2 58% 27 
BHUVANESHWARI 38 F 55 1.45 26.15 19 61% 99% absent 26 2 mild 0 1 61% 26 
SHANMUGAN 40 M 48 1.5 21.33 15 40% 95% moderate 66 8 severe 3 7 36% 66 
MALLIKA 60 F 53 1.45 25.21 18 60% 99% absent 26 1 mild 0 1 60% 26 
SHANKAR 50 M 58 1.7 20.06 22 43% 97% moderate 63 8 severe 3 7 38% 67 
SHANTHI 52 F 46 1.5 20.44 21 26% 92% severe 75 9 severe 4 7 20% 78 
SHIVAMOORTHY 60 M 48 1.35 26.34 16 64% 99% absent 26 2 mild 0 2 64% 26 
VENKATACHALAM 58 M 52 1.4 26.53 18 62% 99% absent 29 2 mild 0 2 62% 29 
GOVINDAMMAL 56 F 55 1.61 21.2 19 34% 95% moderate 35 9 severe 2 7 29% 39 
GAURI 72 F 49 1.58 19.64 22 24% 90% severe 75 8 severe 3 7 18% 79 
MUNUSWAMY 69 M 50 1.5 22.22 20 29% 94% moderate 48 6 severe 2 6 25% 52 
SUBALAKSHMI 46 F 61 1.71 21.4 17 46% 99% mild 36 5 moderate 1 5 46% 40 
SETHURAMAN 45 M 56 1.4 28.57 14 55% 99% absent 20 2 mild 0 2 55% 20 
CHINAMMAL 40 F 60 1.51 25.34 14 61% 98% absent 25 2 mild 0 1 61% 25 
MANIMARAN  55 M 51 1.6 19.92 21 40% 99% mild 33 8 severe 1 6 40% 37 
BALAMANI 68 F 49 1.39 25.36 18 64% 99% absent 28 1 mild 0 1 64% 28 
LINGAM 66 M 50 1.3 29.58 16 66% 99% absent 26 1 mild 0 1 66% 26 
RANI 80 F 46 1.32 26.4 17 45% 99% mild 49 5 moderate 1 4 40% 49 
FATHIMA 60 F 56 1.7 19.3 18 38% 99% mild 44 3 moderate 0 2 38% 47 
JAYALAKSHMI 46 F 49 1.61 18.9 16 26% 95% moderate 60 8 severe 2 7 21% 64 
SARALA 57 F 59 1.5 26.22 18 65% 99% mild 56 2 mild 1 2 60% 56 
RAJESH 50 M 60 1.4 30.61 17 63% 98% absent 20 1 mild 0 1 63% 20 
KIRBAKAVAN 45 M 56 1.45 26.64 15 57% 99% absent 27 2 mild 0 2 57% 27 
MURUGANDAM 35 M 54 1.6 21.09 16 50% 99% mild 38 5 moderate 1 4 49% 42 
RANKUMAR 40 M 56 1.33 31.8 14 65% 98% absent 28 2 mild 0 2 65% 28 
KARTHIK 60 M 47 1.5 20.88 22 40% 97% moderate 66 5 moderate 1 4 35% 70 
SHANMUGAN 65 M 45 1.4 22.95 17 39% 98% mild 39 8 severe 1 8 37% 44 
KRISHNAN 46 M 61 1.51 26.75 14 45% 98% mild 43 5 moderate 1 5 43% 43 
SIDDIQUE 62 M 50 1.6 19.5 14 30% 97% moderate 69 8 severe 2 7 26% 71 
LOGANATHAN 52 M 60 1.5 26.66 19 61% 99% absent 24 2 mild 0 2 61% 24 
SHIVA 60 M 55 1.45 26.15 22 49% 99% mild 43 5 moderate 1 3 47% 46 
RAMU 50 M 58 1.44 27.97 17 63% 98% absent 23 2 mild 0 2 63% 23 
SALAI 56 M 53 1.45 25.21 19 60% 99% absent 25 2 mild 0 1 60% 25 
SALIM 47 M 58 1.5 25.77 20 55% 98% absent 20 1 mild 0 1 55% 20 
LOGANAYAGI 67 M 49 1.53 20.9 16 32% 96% moderate 59 7 severe 1 5 27% 59 
MANJULA 40 F 59 1.51 26.22 17 54% 98% absent 22 2 mild 0 2 54% 22 
KANIKA 34 F 60 1.4 30.61 19 60% 99% absent 21 2 mild 0 1 60% 21 
JAYAVELA 62 M 50 1.55 20.8 20 39% 96% moderate 65 5 moderate 2 4 34% 65 
SRIRAM 70 M 58 1.63 21.83 14 27% 99% mild 38 6 severe 1 4 27% 40 
KARPAGAM 65 F 56 1.7 19.37 20 29% 89% severe 74 9 severe 3 8 23% 77 
VADIVEL 57 F 59 1.58 23.63 21 45% 98% mild 33 5 moderate 1 4 44% 33 
MARY 48 F 49 1.6 19.14 19 39% 99% mild 39 5 moderate 1 5 36% 42 
DINAKAR 67 M 70 1.55 20.8 22 32% 93% severe 73 9 severe 2 7 23% 75 
SAMPATHAN 50 M 46 1.46 21.4 18 65% 99% absent 22 2 mild 0 1 65% 22 
PERUMAL 49 M 56 1.62 21.34 17 55% 99% absent 27 2 mild 0 1 55% 27 
KRISHNAMOORTHY 60 M 49 1.7 16.9 16 44% 97% mild 41 5 moderate 0 4 44% 45 
VELAUDHAM 55 M 49 1.46 22.99 17 60% 99% absent 18 2 mild 0 1 60% 18 
SABARIMUTHU 46 M 57 1.5 25.33 15 61% 99% absent 19 2 mild 0 1 61% 19 
MURUGAN 58 M 54 1.62 20.59 16 40% 99% mild 40 4 moderate 1 3 39% 44 
GUNASEKARAN 46 M 56 1.53 24.3 14 53% 99% absent 28 2 mild 0 1 53% 28 
MUNIANDI 52 M 50 1.6 19.5 22 39% 99% mild 44 5 moderate 1 4 39% 44 
ELUMALAI 49 M 60 1.5 26.66 17 65% 98% absent 27 2 mild 0 1 65% 27 
ELANGOVAN 51 M 55 1.45 26.15 14 62% 99% absent 19 1 mild 0 1 62% 19 
CHINAKUTI 54 M 48 1.5 21.33 20 30% 99% mild 32 5 moderate 1 4 29% 35 
EGAMBARAM 43 M 53 1.45 25.21 18 50% 99% absent 30 2 mild 0 2 50% 30 
VENKATIAH 48 M 66 1.7 20.06 19 22% 92% severe 76 8 severe 3 8 15% 76 
 
